Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study
Aggressive medical care can increase suffering and the health-care burden on patients with advanced haematological malignancies. Our palliative care team has been pioneering an integrated palliative care (IPC) programme for patients with advanced haematological malignancies in Hong Kong since 2018....
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2022-07, Vol.23, p.S10-S10 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S10 |
|---|---|
| container_issue | |
| container_start_page | S10 |
| container_title | The lancet oncology |
| container_volume | 23 |
| creator | Chan, Kwok Ying Gill, Harinder Singh Harry Chan, Thomas Sau Yan Li, Cho Wing Tsang, Kwok Wai Au, Ho Yan Wong, Chi Yan Hui, Chun Him Mok, Lesley Wan Sze |
| description | Aggressive medical care can increase suffering and the health-care burden on patients with advanced haematological malignancies. Our palliative care team has been pioneering an integrated palliative care (IPC) programme for patients with advanced haematological malignancies in Hong Kong since 2018. The aim of the study was to evaluate the effect of IPC on the administration of chemotherapy or other treatments within the 14 days before death; multiple (more than one) emergency department visits within the 90 days before death; multiple (more than one) unplanned hospitalisations within the 90 days before death; and intensive care unit admission within the 90 days before death.
We retrospectively reviewed the outcomes of patients with advanced haematological malignancies who received IPC during the period of Jan 1, 2017, to Dec 31, 2020. Patients who died on the day of referral to palliative care or younger than 18 years were excluded. Our IPC programme comprised: early palliative care referral and advance care planning discussions; baseline and regular assessment of patient's physical and psychospiritual distress and family concerns; consensus for symptom management and supportive services; and regular meetings with haematologists to review and modify care plans for their patients and community providers. Patients matched by disease status and patient characteristics but who did not receive IPC were selected as control in a 1:2 ratio. Descriptive statistics were used to illustrate general patient characteristics, stratified by matching group. Multivariate analyses were used to assess the effect of IPC on the outcomes of interest. The effect of duration of IPC on patient outcomes was also investigated. Ethical approval for this study was issued by the Institutional Review Board of the University of Hong Kong and Hospital Authority Hong Kong West Cluster (reference UW 18–282).
317 patients with advanced haematological malignancies (of whom 105 received IPC) were included for analysis. The primary diagnosis was lymphoma (134 [42%] of 317 patients), leukaemia (106 [33%]), myelodysplastic syndrome (46 [15%]), and myeloma (31 [10%]). The use of IPC was associated with less multiple emergency department visits (odds ratio 0·19 [95% CI 0·16–0·23]; p=0·019], reduced multiple unplanned hospitalisations (0·24 [0·19–0·31]; p=0·0021), and lower risk of intensive care unit admission (0·12 [0·08–0·18]; p=0·0032) within the 90 days before death, and decreased need of chemot |
| doi_str_mv | 10.1016/S1470-2045(22)00409-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2688975360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204522004090</els_id><sourcerecordid>2688975360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2290-d5e6cb205047c4f970bf0a8ade20f1735435ef501790d6474f28e59c0ef4c3</originalsourceid><addsrcrecordid>eNqFUctq3TAQNSWFJmk-oSDoJl24HetKfmQTQmibQKDQZi8m0shXwbZcSfeW_FM_srLdfVYSOo8ZnVMUHyr4XEFVf_lViQZKDkJecv4JQEBXwpviND-LUoq2PVnvG-VdcRbjM0DVVCBPi7_344w6MW-ZmxL1ARMZNuMwOEzuSExjoAwx1IdEDCfDsO8DxbiAIxmncdhI1ocsTI6mFNkfl_YMzREnnf32SCMmP_h-pY84uH7KkKN4xZAFSsHHmfQ6MTP1Pos0Riq1nzI2sJgO5uV98dbiEOni_3le_Pz29fH2rnz48f3-9uah1Jx3UBpJtX7iIEE0WtiugScL2KIhDrZqdlLsJFmZI-jA1Dkky1uSnQayQu_Oi4-b6Rz87wPFpJ79IUx5nuJ123aN3NWQWXJj6bx5DGTVHNyI4UVVoJZW1NqKWiJXnKu1FbXorjcd5f2PjoKKOYUlJBfy_5Xx7hWHf1v0l-s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2688975360</pqid></control><display><type>article</type><title>Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study</title><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Chan, Kwok Ying ; Gill, Harinder Singh Harry ; Chan, Thomas Sau Yan ; Li, Cho Wing ; Tsang, Kwok Wai ; Au, Ho Yan ; Wong, Chi Yan ; Hui, Chun Him ; Mok, Lesley Wan Sze</creator><creatorcontrib>Chan, Kwok Ying ; Gill, Harinder Singh Harry ; Chan, Thomas Sau Yan ; Li, Cho Wing ; Tsang, Kwok Wai ; Au, Ho Yan ; Wong, Chi Yan ; Hui, Chun Him ; Mok, Lesley Wan Sze</creatorcontrib><description>Aggressive medical care can increase suffering and the health-care burden on patients with advanced haematological malignancies. Our palliative care team has been pioneering an integrated palliative care (IPC) programme for patients with advanced haematological malignancies in Hong Kong since 2018. The aim of the study was to evaluate the effect of IPC on the administration of chemotherapy or other treatments within the 14 days before death; multiple (more than one) emergency department visits within the 90 days before death; multiple (more than one) unplanned hospitalisations within the 90 days before death; and intensive care unit admission within the 90 days before death.
We retrospectively reviewed the outcomes of patients with advanced haematological malignancies who received IPC during the period of Jan 1, 2017, to Dec 31, 2020. Patients who died on the day of referral to palliative care or younger than 18 years were excluded. Our IPC programme comprised: early palliative care referral and advance care planning discussions; baseline and regular assessment of patient's physical and psychospiritual distress and family concerns; consensus for symptom management and supportive services; and regular meetings with haematologists to review and modify care plans for their patients and community providers. Patients matched by disease status and patient characteristics but who did not receive IPC were selected as control in a 1:2 ratio. Descriptive statistics were used to illustrate general patient characteristics, stratified by matching group. Multivariate analyses were used to assess the effect of IPC on the outcomes of interest. The effect of duration of IPC on patient outcomes was also investigated. Ethical approval for this study was issued by the Institutional Review Board of the University of Hong Kong and Hospital Authority Hong Kong West Cluster (reference UW 18–282).
317 patients with advanced haematological malignancies (of whom 105 received IPC) were included for analysis. The primary diagnosis was lymphoma (134 [42%] of 317 patients), leukaemia (106 [33%]), myelodysplastic syndrome (46 [15%]), and myeloma (31 [10%]). The use of IPC was associated with less multiple emergency department visits (odds ratio 0·19 [95% CI 0·16–0·23]; p=0·019], reduced multiple unplanned hospitalisations (0·24 [0·19–0·31]; p=0·0021), and lower risk of intensive care unit admission (0·12 [0·08–0·18]; p=0·0032) within the 90 days before death, and decreased need of chemotherapy or other treatments within the 14 days before death (0·34 [0·25–0·46]; p=0·0012). Receiving IPC for more than 90 days was associated with 2% fewer multiple emergency department visits, 12% less multiple unplanned hospitalisations, 3% less intensive care unit admissions, and 11% less need of chemotherapy or other treatments in the defined near-death intervals.
This study was limited by its retrospective design and the scarcity of details on the frequency and intensity of the palliative care service. Despite these limitations, we found that the use of IPC service was associated with reduced need for acute and aggressive medical services in patients with advanced haematological malignancies.
None.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(22)00409-0</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Blood cancer ; Chemotherapy ; Death ; Emergency medical care ; Hematology ; Hospitalization ; Intensive care ; Leukemia ; Lymphoma ; Myelodysplastic syndrome ; Myelodysplastic syndromes ; Myeloma ; Palliation ; Palliative care ; Patients ; Statistical analysis ; Symptom management</subject><ispartof>The lancet oncology, 2022-07, Vol.23, p.S10-S10</ispartof><rights>2022 Elsevier Ltd</rights><rights>2022. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2290-d5e6cb205047c4f970bf0a8ade20f1735435ef501790d6474f28e59c0ef4c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2688975360?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64389,72469</link.rule.ids></links><search><creatorcontrib>Chan, Kwok Ying</creatorcontrib><creatorcontrib>Gill, Harinder Singh Harry</creatorcontrib><creatorcontrib>Chan, Thomas Sau Yan</creatorcontrib><creatorcontrib>Li, Cho Wing</creatorcontrib><creatorcontrib>Tsang, Kwok Wai</creatorcontrib><creatorcontrib>Au, Ho Yan</creatorcontrib><creatorcontrib>Wong, Chi Yan</creatorcontrib><creatorcontrib>Hui, Chun Him</creatorcontrib><creatorcontrib>Mok, Lesley Wan Sze</creatorcontrib><title>Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study</title><title>The lancet oncology</title><description>Aggressive medical care can increase suffering and the health-care burden on patients with advanced haematological malignancies. Our palliative care team has been pioneering an integrated palliative care (IPC) programme for patients with advanced haematological malignancies in Hong Kong since 2018. The aim of the study was to evaluate the effect of IPC on the administration of chemotherapy or other treatments within the 14 days before death; multiple (more than one) emergency department visits within the 90 days before death; multiple (more than one) unplanned hospitalisations within the 90 days before death; and intensive care unit admission within the 90 days before death.
We retrospectively reviewed the outcomes of patients with advanced haematological malignancies who received IPC during the period of Jan 1, 2017, to Dec 31, 2020. Patients who died on the day of referral to palliative care or younger than 18 years were excluded. Our IPC programme comprised: early palliative care referral and advance care planning discussions; baseline and regular assessment of patient's physical and psychospiritual distress and family concerns; consensus for symptom management and supportive services; and regular meetings with haematologists to review and modify care plans for their patients and community providers. Patients matched by disease status and patient characteristics but who did not receive IPC were selected as control in a 1:2 ratio. Descriptive statistics were used to illustrate general patient characteristics, stratified by matching group. Multivariate analyses were used to assess the effect of IPC on the outcomes of interest. The effect of duration of IPC on patient outcomes was also investigated. Ethical approval for this study was issued by the Institutional Review Board of the University of Hong Kong and Hospital Authority Hong Kong West Cluster (reference UW 18–282).
317 patients with advanced haematological malignancies (of whom 105 received IPC) were included for analysis. The primary diagnosis was lymphoma (134 [42%] of 317 patients), leukaemia (106 [33%]), myelodysplastic syndrome (46 [15%]), and myeloma (31 [10%]). The use of IPC was associated with less multiple emergency department visits (odds ratio 0·19 [95% CI 0·16–0·23]; p=0·019], reduced multiple unplanned hospitalisations (0·24 [0·19–0·31]; p=0·0021), and lower risk of intensive care unit admission (0·12 [0·08–0·18]; p=0·0032) within the 90 days before death, and decreased need of chemotherapy or other treatments within the 14 days before death (0·34 [0·25–0·46]; p=0·0012). Receiving IPC for more than 90 days was associated with 2% fewer multiple emergency department visits, 12% less multiple unplanned hospitalisations, 3% less intensive care unit admissions, and 11% less need of chemotherapy or other treatments in the defined near-death intervals.
This study was limited by its retrospective design and the scarcity of details on the frequency and intensity of the palliative care service. Despite these limitations, we found that the use of IPC service was associated with reduced need for acute and aggressive medical services in patients with advanced haematological malignancies.
None.</description><subject>Blood cancer</subject><subject>Chemotherapy</subject><subject>Death</subject><subject>Emergency medical care</subject><subject>Hematology</subject><subject>Hospitalization</subject><subject>Intensive care</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic syndromes</subject><subject>Myeloma</subject><subject>Palliation</subject><subject>Palliative care</subject><subject>Patients</subject><subject>Statistical analysis</subject><subject>Symptom management</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFUctq3TAQNSWFJmk-oSDoJl24HetKfmQTQmibQKDQZi8m0shXwbZcSfeW_FM_srLdfVYSOo8ZnVMUHyr4XEFVf_lViQZKDkJecv4JQEBXwpviND-LUoq2PVnvG-VdcRbjM0DVVCBPi7_344w6MW-ZmxL1ARMZNuMwOEzuSExjoAwx1IdEDCfDsO8DxbiAIxmncdhI1ocsTI6mFNkfl_YMzREnnf32SCMmP_h-pY84uH7KkKN4xZAFSsHHmfQ6MTP1Pos0Riq1nzI2sJgO5uV98dbiEOni_3le_Pz29fH2rnz48f3-9uah1Jx3UBpJtX7iIEE0WtiugScL2KIhDrZqdlLsJFmZI-jA1Dkky1uSnQayQu_Oi4-b6Rz87wPFpJ79IUx5nuJ123aN3NWQWXJj6bx5DGTVHNyI4UVVoJZW1NqKWiJXnKu1FbXorjcd5f2PjoKKOYUlJBfy_5Xx7hWHf1v0l-s</recordid><startdate>202207</startdate><enddate>202207</enddate><creator>Chan, Kwok Ying</creator><creator>Gill, Harinder Singh Harry</creator><creator>Chan, Thomas Sau Yan</creator><creator>Li, Cho Wing</creator><creator>Tsang, Kwok Wai</creator><creator>Au, Ho Yan</creator><creator>Wong, Chi Yan</creator><creator>Hui, Chun Him</creator><creator>Mok, Lesley Wan Sze</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202207</creationdate><title>Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study</title><author>Chan, Kwok Ying ; Gill, Harinder Singh Harry ; Chan, Thomas Sau Yan ; Li, Cho Wing ; Tsang, Kwok Wai ; Au, Ho Yan ; Wong, Chi Yan ; Hui, Chun Him ; Mok, Lesley Wan Sze</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2290-d5e6cb205047c4f970bf0a8ade20f1735435ef501790d6474f28e59c0ef4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Blood cancer</topic><topic>Chemotherapy</topic><topic>Death</topic><topic>Emergency medical care</topic><topic>Hematology</topic><topic>Hospitalization</topic><topic>Intensive care</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic syndromes</topic><topic>Myeloma</topic><topic>Palliation</topic><topic>Palliative care</topic><topic>Patients</topic><topic>Statistical analysis</topic><topic>Symptom management</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chan, Kwok Ying</creatorcontrib><creatorcontrib>Gill, Harinder Singh Harry</creatorcontrib><creatorcontrib>Chan, Thomas Sau Yan</creatorcontrib><creatorcontrib>Li, Cho Wing</creatorcontrib><creatorcontrib>Tsang, Kwok Wai</creatorcontrib><creatorcontrib>Au, Ho Yan</creatorcontrib><creatorcontrib>Wong, Chi Yan</creatorcontrib><creatorcontrib>Hui, Chun Him</creatorcontrib><creatorcontrib>Mok, Lesley Wan Sze</creatorcontrib><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chan, Kwok Ying</au><au>Gill, Harinder Singh Harry</au><au>Chan, Thomas Sau Yan</au><au>Li, Cho Wing</au><au>Tsang, Kwok Wai</au><au>Au, Ho Yan</au><au>Wong, Chi Yan</au><au>Hui, Chun Him</au><au>Mok, Lesley Wan Sze</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study</atitle><jtitle>The lancet oncology</jtitle><date>2022-07</date><risdate>2022</risdate><volume>23</volume><spage>S10</spage><epage>S10</epage><pages>S10-S10</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>Aggressive medical care can increase suffering and the health-care burden on patients with advanced haematological malignancies. Our palliative care team has been pioneering an integrated palliative care (IPC) programme for patients with advanced haematological malignancies in Hong Kong since 2018. The aim of the study was to evaluate the effect of IPC on the administration of chemotherapy or other treatments within the 14 days before death; multiple (more than one) emergency department visits within the 90 days before death; multiple (more than one) unplanned hospitalisations within the 90 days before death; and intensive care unit admission within the 90 days before death.
We retrospectively reviewed the outcomes of patients with advanced haematological malignancies who received IPC during the period of Jan 1, 2017, to Dec 31, 2020. Patients who died on the day of referral to palliative care or younger than 18 years were excluded. Our IPC programme comprised: early palliative care referral and advance care planning discussions; baseline and regular assessment of patient's physical and psychospiritual distress and family concerns; consensus for symptom management and supportive services; and regular meetings with haematologists to review and modify care plans for their patients and community providers. Patients matched by disease status and patient characteristics but who did not receive IPC were selected as control in a 1:2 ratio. Descriptive statistics were used to illustrate general patient characteristics, stratified by matching group. Multivariate analyses were used to assess the effect of IPC on the outcomes of interest. The effect of duration of IPC on patient outcomes was also investigated. Ethical approval for this study was issued by the Institutional Review Board of the University of Hong Kong and Hospital Authority Hong Kong West Cluster (reference UW 18–282).
317 patients with advanced haematological malignancies (of whom 105 received IPC) were included for analysis. The primary diagnosis was lymphoma (134 [42%] of 317 patients), leukaemia (106 [33%]), myelodysplastic syndrome (46 [15%]), and myeloma (31 [10%]). The use of IPC was associated with less multiple emergency department visits (odds ratio 0·19 [95% CI 0·16–0·23]; p=0·019], reduced multiple unplanned hospitalisations (0·24 [0·19–0·31]; p=0·0021), and lower risk of intensive care unit admission (0·12 [0·08–0·18]; p=0·0032) within the 90 days before death, and decreased need of chemotherapy or other treatments within the 14 days before death (0·34 [0·25–0·46]; p=0·0012). Receiving IPC for more than 90 days was associated with 2% fewer multiple emergency department visits, 12% less multiple unplanned hospitalisations, 3% less intensive care unit admissions, and 11% less need of chemotherapy or other treatments in the defined near-death intervals.
This study was limited by its retrospective design and the scarcity of details on the frequency and intensity of the palliative care service. Despite these limitations, we found that the use of IPC service was associated with reduced need for acute and aggressive medical services in patients with advanced haematological malignancies.
None.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><doi>10.1016/S1470-2045(22)00409-0</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2022-07, Vol.23, p.S10-S10 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_journals_2688975360 |
| source | ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Blood cancer Chemotherapy Death Emergency medical care Hematology Hospitalization Intensive care Leukemia Lymphoma Myelodysplastic syndrome Myelodysplastic syndromes Myeloma Palliation Palliative care Patients Statistical analysis Symptom management |
| title | Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A51%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20integrated%20palliative%20care%20in%20acute%20and%20aggressive%20medical%20care%20for%20patients%20with%20advanced%20haematological%20malignancies:%20a%20retrospective%20matched%20case-control%20study&rft.jtitle=The%20lancet%20oncology&rft.au=Chan,%20Kwok%20Ying&rft.date=2022-07&rft.volume=23&rft.spage=S10&rft.epage=S10&rft.pages=S10-S10&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(22)00409-0&rft_dat=%3Cproquest_cross%3E2688975360%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2688975360&rft_id=info:pmid/&rft_els_id=S1470204522004090&rfr_iscdi=true |